Beyond Next Ventures has invested in GramEye, a medtech startup that utilizes AI to revolutionize infectious disease diagnostics.
About GramEye
GramEye Inc., headquartered in Ibaraki, Osaka and led by CEO Yu Hiraoka, is an innovative medtech startup focused on revolutionizing infectious disease diagnostics through the application of artificial intelligence (AI) and robotics. The company has developed an advanced system called Mycrium, which fully automates the microbial Gram staining and analysis process traditionally performed by clinical laboratory technologists.
Mycrium offers significant advancements in the speed and accuracy of bacterial identification, capable of analyzing microscopic images to detect and classify bacteria with remarkable precision. This technology enables clinicians to obtain diagnostic results in as little as 10 minutes per sample, thereby enhancing treatment outcomes and promoting the appropriate use of antibiotics. By addressing critical issues such as antimicrobial resistance (AMR), GramEye's innovations also contribute to operational efficiency in clinical settings.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
The medical technology industry in Japan has been experiencing rapid growth, driven by the increasing demand for advanced healthcare solutions and the integration of cutting-edge technology into clinical practice. Amid a global cont
Similar Deals
Kyoto University Innovation Capital Co., Ltd. → Toregem Biopharma, Inc.
2024
Beyond Next Ventures Inc.
invested in
GramEye Inc.
in 2025
in a Series B deal